EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma

Gao, Jie; Yu, Yongsheng; Zhang, Yingying; Song, Jinjing; Chen, Huaiwen; Li, Wei; Qian, Weizhu; Deng, Li; Kou, Geng; Chen, Jianming; Guo, Yajun

doi:10.1016/j.biomaterials.2011.09.035

Cited by 101 publications

(67 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In vitro uptake and cytotoxicity of EGF-GemC18-NPs realised with different human breast adenocarcinoma cell lines showed a correlation between EGFR density on the cell surface and cell uptake and toxicity. 86,98,100,101 In cell culture, EGF-GemC18-NPs uptake by tumour cells was correlated to the EGFR density, whereas the uptake of untargeted GemC18-NPs …”

Section: Lipophilic Prodrugsmentioning

confidence: 99%

Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications

2012

View full text Add to dashboard Cite

Gemcitabine, an anticancer agent which acts against a wide range of solid tumors, is known to be rapidly deaminated in blood to the inactive metabolite 2',2'-difluorodeoxyuridine and to be rapidly excreted by the urine. Moreover, many cancers develop resistance against this drug, such as loss of transporters and kinases responsible for the first phosphorylation step. To increase its therapeutic levels, gemcitabine is administered at high dose (1000mg/m²) causing sides effects (neutropenia, nausea…).To improve its metabolic stability, its cytotoxic activity and to

show abstract

Section: Lipophilic Prodrugsmentioning

confidence: 99%

Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications

2012

View full text Add to dashboard Cite

show abstract

“…5). Capacity for tumor sphere formation is considered to be associated with CSC percentage (21). In OVCAR-3 cells, CD133-SAL-NPs resulted in a decreased number of tumor spheres than SAL-NPs and salinomycin (P<0.01; Fig.…”

Section: Cd133 + Ovarian Cancer Cells Possess the Properties Of Ovarianmentioning

confidence: 99%

The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles

Huang

Deng

2018

Oncol Lett

View full text Add to dashboard Cite

Abstract. Ovarian cancer is the most lethal gynecologic malignancy, and ovarian cancer stem cells (CSCs) serve a pivotal function in the metastasis and recurrence of ovarian cancer. Multiple previous studies have validated CD133 as a marker of ovarian CSCs. Although salinomycin is a promising therapeutic agent that has been demonstrated to kill CSCs in various types of cancer, poor aqueous solubility hampers its clinical application. The present study used salinomycin-loaded poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles conjugated with CD133 antibodies (CD133-SAL-NP) to eliminate CD133 + ovarian CSCs. The results revealed that CD133-SAL-NPs were of an appropriate size (149.2 nm) and exhibited sustained drug release. CD133-SAL-NPs efficiently bound to CD133 + ovarian cancer cells, resulting in an increased cytotoxic effect in CD133 + ovarian cancer cells, compared with the untargeted SAL-NPs and salinomycin. CD133-SAL-NPs reduced the percentage of CD133 + ovarian CSCs in ovarian cells more effectively than treatment with salinomycin or SAL-NPs, suggesting that CD133-SAL-NP targeted CD133 + ovarian CSCs. In nude mice bearing ovarian cancer xenografts, CD133-SAL-NPs exerted improved therapeutic effects compared with SAL-NPs and salinomycin. Thus, CD133 was demonstrated to be a promising target for drug delivery to ovarian CSCs, and may be useful as an agent to inhibit the growth of ovarian cancer by targeting CD133 + ovarian CSCs. CD133-SAL-NPs may therefore represent a promising approach for the treatment of ovarian cancer.

show abstract

“…The ability of tumorsphere formation in suspension cultures is reported to be correlated with the proportion of CSCs. 35 As shown in Figure 6A and C, Ap-SAL-NP treatment resulted in a fivefold decrease in the number of Saos-2 mammospheres relative to the untreated control. Moreover, Ap-SAL-NP treatment resulted in much fewer mammospheres compared with salinomycin (P0.01) and SAL-NP (P0.001).…”

Section: The Effect Of Nanoparticles On the Proportion Of Cscs With Tmentioning

confidence: 77%

“…10 CSCs phenotypes can also be utilized to fulfill the aim of specifically targeting CSCs, similar to the tumor associated antigen such as epidermal growth factor receptor or HER2. [33][34][35] CD133 is also one of the best documented CSCs markers. Recently, Bourseau-Guilmain et al developed lipid nanocapsules (LNCs) conjugated with CD133 monoclonal antibody (immune-LNCs).…”

Section: Discussionmentioning

confidence: 99%

Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells

Ni¹,

Xiong²,

Zhang³

et al. 2015

IJN

Self Cite

View full text Add to dashboard Cite

Background Cancer stem cells (CSCs) possess the characteristics associated with normal stem cells and are responsible for cancer initiation, recurrence, and metastasis. CD133 is regarded as a CSCs marker of osteosarcoma, which is the most common primary bone malignancy in childhood and adolescence. Salinomycin, a polyether ionophore antibiotic, has been shown to kill various CSCs, including osteosarcoma CSCs. However, salinomycin displayed poor aqueous solubility that hinders its clinical application. The objective of this study was to develop salinomycin-loaded nanoparticles to eliminate CD133 + osteosarcoma CSCs. Methods The salinomycin-loaded PEGylated poly(lactic-co-glycolic acid) nanoparticles (SAL-NP) conjugated with CD133 aptamers (Ap-SAL-NP) were developed by an emulsion/solvent evaporation method, and the targeting and cytotoxicity of Ap-SAL-NP to CD133 + osteosarcoma CSCs were evaluated. Results The nanoparticles are of desired particle size (~150 nm), drug encapsulation efficiency (~50%), and drug release profile. After 48 hours treatment of the Saos-2 CD133 + osteosarcoma cells with drugs formulated in Ap-SAL-NP, SAL-NP, and salinomycin, the concentrations needed to kill 50% of the incubated cells were found to be 2.18, 10.72, and 5.07 μg/mL, respectively, suggesting that Ap-SAL-NP could be 4.92 or 2.33 fold more effective than SAL-NP or salinomycin, respectively. In contrast, Ap-SAL-NP was as effective as SAL-NP, and less effective than salinomycin in Saos-2 CD133 − cells, suggesting that Ap-SAL-NP possess specific cytotoxicity toward Saos-2 CD133 + cells. Ap-SAL-NP showed the best therapeutic effect in Saos-2 osteosarcoma xenograft mice, compared with SAL-NP or salinomycin. Significantly, Ap-SAL-NP could selectively kill CD133 + osteosarcoma CSCs both in vitro and in vivo, as reflected by the tumorsphere formation and proportion of Saos-2 CD133 + cells. Conclusion Our results suggest that CD133 is a potential target for drug delivery to osteosarcoma CSCs and that it is possible to significantly inhibit the osteosarcoma growth by killing CD133 + osteosarcoma CSCs. We demonstrated that Ap-SAL-NP have the potential to target and kill CD133 + osteosarcoma CSCs.

show abstract

EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma

Cited by 101 publications

References 32 publications

Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications

Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications

The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles

Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells

Contact Info

Product

Resources

About